Long-Term Follow-Up of Patients With Follicular Lymphoma Receiving Single-Agent Rituximab at Two Different Schedules in Trial SAKK 35/98

Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab

(2009) S. P. Hilchey et al.   BLOOD

Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab

(2008) I. F. Khouri et al.   BLOOD

High-dose therapy followed by autologous purged stem cell transplantation and doxorubicin-based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS with final results after a median follow-up of 9 years

(2008) E. Gyan et al.   BLOOD

Follicular Lymphoma, Survival, and Rituximab: Is It Time to Declare Victory?

(2008) Sandra J. Horning   JOURNAL OF CLINICAL ONCOLOGY

Follicular Lymphoma Revisited

(2008) Saul A. Rosenberg   JOURNAL OF CLINICAL ONCOLOGY

Long-term molecular remissions in patients with indolent lymphoma treated with rituximab as a single agent or in combination with interferon alpha-2a: A randomized phase II study from the Nordic Lymphoma Group

(2008) Eva Kimby et al.   LEUKEMIA & LYMPHOMA